Clinical Trials on Hereditary Renal Papillary Cancer

Total 1616 results

Jonsson Comprehensive Cancer Center
BeiGene; Driven To Cure

Withdrawn

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditions

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
National Cancer Institute (NCI)

Completed

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

HLRCC | Sporadic Papillary Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
National Cancer Institute (NCI)

Recruiting

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Sporadic Papillary Renal Cell Carcinoma

United States
DeuterOncology

Recruiting

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

Adult Solid Tumor | Lung Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Non-small Cell Carcinoma | Refractory Tumor | Hereditary Renal Papillary Cancer

France, Belgium, Netherlands
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
Australian and New Zealand Urogenital and Prostate...

Recruiting

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell Carcinoma

Australia
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer

Stage II Papillary Thyroid Cancer | Stage III Papillary Thyroid Cancer | Stage I Papillary Thyroid Cancer

United States
Australian and New Zealand Urogenital and Prostate...
Bristol-Myers Squibb

Active, not recruiting

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation Carcinoma

Australia
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditions

United States
Exelixis

Completed

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Renal Cell Carcinoma | Papillary Thyroid Cancer | Follicular Thyroid Cancer | Huerthle Cell Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

Recurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Stage IV Renal Cell Cancer AJCC v8 | Metastatic Papillary Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Kidney Cancer

United States
University of Washington
National Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...

Completed

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Recurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
National Cancer Institute (NCI)

Terminated

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Papillary Renal Cell Carcinoma

United States
University Health Network, Toronto
University of British Columbia; Canadian Institutes of Health Research (CIHR); CHU de Quebec-Universite Laval and other collaborators

Recruiting

Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer

Papillary Thyroid Carcinoma | Papillary Thyroid Cancer | Papillary Microcarcinoma of the Thyroid

Canada
National Cancer Institute (NCI)

Terminated

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Renal Cell Carcinoma | Renal Cell Cancer | Hereditary Leiomyomatosis

United States
Mayo Clinic

Active, not recruiting

Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

Papillary Thyroid Cancer | Papillary Thyroid Microcarcinoma

United States
Massachusetts General Hospital

Completed

Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study

Papillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node Metastasis

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer

United States
National Cancer Institute (NCI)

Terminated

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid Cancer

United States
Grupo Espanol de Tumores Neuroendocrinos
MFAR

Active, not recruiting

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)

Metastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular Carcinoma

Spain
National Cancer Institute (NCI)

Completed

Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine

Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer

United States
Chinese PLA General Hospital

Not yet recruiting

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

Papillary Thyroid Cancer
Assiut University

Unknown

The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma (pCND)

Papillary Thyroid Cancer

Egypt
National Cancer Institute (NCI)

Terminated

Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer

Thyroid Cancer | Low-risk Papillary Thyroid Cancer | Endocrine Malignancy

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
Jinan Military General Hospital

Completed

Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy

Thyroidectomy | Thyroid Papillary Carcinoma

China
Fujian Medical University

Unknown

Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma

Thyroid Papillary Carcinoma

China
Nanfang Hospital, Southern Medical University

Recruiting

A Clinical Study of Transaxillary Endoscopic and Open Thyroidectomy for PTC

Papillary Thyroid Cancer

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Stage I Renal Cell Cancer | Childhood Renal Cell Carcinoma | Stage II Renal Cell Cancer | Stage I Renal Wilms Tumor and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico
National Taiwan University Hospital

Recruiting

Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer

Thyroid Cancer | Papillary Thyroid Cancer | Follicular Thyroid Cancer

Taiwan
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

Recurrent Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma

United States, Canada
Children's Hospital of Philadelphia
United States Department of Defense

Recruiting

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Pediatric Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer

United States
Helsinki University Central Hospital

Active, not recruiting

a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS

to Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm
National Cancer Institute (NCI)

Recruiting

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc) | Papillary Renal Cell Carcinoma (Prcc)

United States
Hoffmann-La Roche

Completed

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Neoplasms

United States, France, Italy, Netherlands
University of Calgary
Alberta Health services; Qualisure Diagnostics Inc.

Not yet recruiting

Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples

Papillary Thyroid Cancer

Canada
University of California, Los Angeles

Recruiting

Molecular Analysis for Precision Surgery in Thyroid Cancer Trial (MAPS)

Papillary Thyroid Cancer

United States
Basaksehir Cam & Sakura Şehir Hospital

Completed

Papillary Thyroid Cancer and Central Lymp Node Dissection

Papillary Thyroid Cancer

Turkey
CHU de Reims

Completed

Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014 (OTCancer)

Papillary Thyroid Cancer

France
Heidelberg University

Completed

BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

Thyroid Cancer
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR); Ontario Ministry of Health and...

Completed

Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer

Thyroid Cancer

Canada
Peking University Cancer Hospital & Institute

Completed

Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer

Thyroid Cancer
University Health Network, Toronto
Ontario Ministry of Health and Long Term Care; Canadian Cancer Society (CCS)

Recruiting

Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer (AS-PTC)

Thyroid Cancer Stage I

Canada
University of Texas Southwestern Medical Center
National Cancer Institute (NCI); Howard Hughes Medical Institute

Recruiting

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

Kidney Cancer | Renal Cell Carcinoma | Urothelial Carcinoma | Hereditary Leiomyomatosis and Renal Cell Cancer | Metastatic Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | HLRCC | Clear Cell Carcinoma | Metastatic Kidney Cancer | Fumarate Hydratase Deficiency | Succinate...

United States
UNICANCER

Completed

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Kidney Cancer

France

Clinical Trials on Hereditary Renal Papillary Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations